logo-loader
RNS
Collagen Solutions PLC

Collagen Sol PLC - Collagen Solutions Acquired by Rosen’s Diversified

RNS Number : 5425C
Collagen Solutions PLC
20 October 2020
 

 

 

20 October 2020

 

Collagen Solutions plc

("Collagen Solutions" or the "Company")

 

Collagen Solutions Plc Acquired by Rosen's Diversified, Inc.

 

Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that today Rosen's Diversified, Inc. ("RDI") declared that its offer to acquire Collagen Solutions plc (the "Offer") had become wholly unconditional and as a result, Collagen Solutions will become part of the RDI Group.

 

RDI is a multi-billion dollar, family-owned and controlled business, headquartered in Minnesota near the Company's U.S. offices. RDI sells a broad range of food, agricultural and scientific products into more than 30 countries, across five continents, and has over 4,500 employees. Collagen Solutions will become part of RDI's life sciences division, which includes Scientific Life Solutions ("SLS"), a supplier of critical components to the bioresearch and biomedical fields.

 

Jamal Rushdy, CEO of Collagen Solutions said: "We have made tremendous progress in our vision to be the industry's first choice for regenerative biomaterials. We believe that being part of RDI will generate significant growth opportunities and create enhanced value for the benefit of all stakeholders and in particular our employees, customers and suppliers. I am optimistic and excited for the potential for continued momentum and greater opportunity for Collagen Solutions." 

 

Wade Rosen, Director of RDI and Executive Vice President of Corporate Development of SLS said: "Collagen Solutions represents an attractive strategic and cultural fit with SLS and we have been highly impressed by the long-term vision and ethos of the Company. The successful completion of the Offer will now provide a foundation for SLS to become a major tissue provider in North America, leveraging the RDI Group's local porcine and bovine harvest, logistics and distribution capabilities in the United States. Collagen's international presence will also provide a platform for SLS to extend its supply of porcine and bovine tissue into the EMEA and APAC regions."

 

England & Company, LLC and Goodbody Stockbrokers UC acted, in relation to the Offer, as joint financial advisers to Collagen Solutions.  Shepherd and Wedderburn LLP acted as legal adviser to Collagen Solutions.

 

Strand Hanson and Faegre Drinker acted, in relation to the Offer, as sole financial adviser and legal adviser to RDI, respectively.

 

Enquiries:

Collagen Solutions Plc
Jamal Rushdy, CEO
Hilary Spence, CFO

via Walbrook

England & Company LLC
(Joint Financial Adviser to Collagen Solutions Plc)
Craig England
Paul Teitelbaum

Tel: +1 (212) 235-0850

Goodbody Stockbrokers UC
(Rule 3 Adviser and Joint Financial Adviser to Collagen Solutions Plc)
Stephen Kane
Christopher McAuliffe

Tel: +353 (0) 1 667 0400

Cenkos Securities plc
(Nominated Adviser and Broker to Collagen Solutions Plc)
Giles Balleny
Max Gould

Tel: +44 (0) 207 397 8900

Walbrook PR Ltd
(Financial PR adviser to Collagen Solutions Plc)
Anna Dunphy

Tel: +44 (0) 207 933 8780
or collagen@walbrookpr.com

Mob: +44 (0) 7876 741 001

Rosen's Diversified, Inc.
David Krawitz, Director of Strategy, Operations and Sales

Tel: +1 (612) 406-5181

Strand Hanson Limited
(Financial Adviser to Rosen's Diversified, Inc.)
Stuart Faulkner
Matthew Chandler
James Dance
Jack Botros

Tel: +44 (0) 207 409 3494

Important Notice

England & Company LLC, through its wholly owned subsidiary, England Securities, LLC, is acting as joint financial adviser to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of England & Company LLC nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither England & Company LLC nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of England & Company LLC in connection with this announcement, any statement contained herein or otherwise.

Goodbody Stockbrokers UC, trading as Goodbody, which is regulated in Ireland by the Central Bank of Ireland and in the UK by the Financial Conduct Authority, is acting as sole Rule 3 adviser and joint financial adviser to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of Goodbody Stockbrokers UC nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein. Neither Goodbody Stockbrokers UC nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Goodbody Stockbrokers UC in connection with this announcement, any statement contained herein or otherwise.

Cenkos Securities plc, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively as nominated adviser and broker to Collagen and no-one else in connection with the Offer and other matters described in this announcement and will not be responsible to anyone other than Collagen for providing the protections afforded to clients of Cenkos Securities plc nor for providing advice in relation to the Offer, the contents of this announcement or any other matter referred to herein.  Neither Cenkos Securities plc nor any of its subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Cenkos Securities plc in connection with this announcement, any statement contained herein or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQDGBDGLXBDGGC
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

6 min read